Chronic Kidney Disease (CKD) Drugs Market Size, Share, Growth, and Industry Analysis, By Type (ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers: BREVIBLOC, Bystolic, Others) By Application (Hospitals, Specialty Clinics) and Regional Forecast to 2035

CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET OVERVIEW

The global Chronic Kidney Disease (CKD) Drugs Market size estimated at USD 14715.69 million in 2026 and is projected to reach USD 17404.23 million by 2035, growing at a CAGR of 1.7% from 2026 to 2035.

The Chronic Kidney Disease Drugs Market focuses on developing treatments for CKD progressive condition of a gradual loss of kidney function. The market involves medications like ACE inhibitors, ARBs, and newer agents such as SGLT2 inhibitors and endothelin receptor antagonists, aimed at slowing disease progression and managing symptoms. Fueled by increasing CKD prevalence due to diabetes and hypertension, the market is experiencing exponential growth. Emerging enhancements focus on personalized therapies and novel drug approvals to improve patient outcomes. Key players such as AstraZeneca, Novo Nordisk, and Travere Therapeutics take the lead in innovative practices in this changing industry.

• • 

    Request a Free sample to learn more about this report.

KEY FINDINGS

• Market Size and Growth: The Chronic Kidney Disease (CKD) Drugs Market size was USD 14227.83 Million in 2024, is projected to grow to USD 14469.71 Million by 2025 and exceed USD 16827.24 Million by 2033, with a CAGR of 1.7%.

• Key Market Driver: Rising prevalence of diabetes and hypertension is fueling demand, with over 537 million adults worldwide living with diabetes in 2023 according to IDF.

• Major Market Restraint: High treatment costs and limited access remain barriers, as nearly 50% of patients in low-income countries lack consistent access to essential nephrology medications.

• Emerging Trends: Increased adoption of SGLT2 inhibitors in CKD therapy is notable, with clinical trial enrollments crossing 20,000 patients globally in the last five years. Another trend is growing investment in biologics, with over 120 pipeline drugs under development targeting renal pathways.

• Regional Leadership: North America leads the market, supported by high disease burden—about 37 million U.S. adults are estimated to have CKD, accounting for nearly 15% of the adult population.

• Competitive Landscape: The sector is moderately consolidated, with more than 15 major pharmaceutical companies dominating global sales. AstraZeneca and Bayer hold significant shares with widely prescribed therapies.

• Market Segmentation: By drug class, ACE inhibitors and ARBs account for over 35% of prescriptions, highlighting their dominance as frontline therapy for managing CKD progression.

• Recent Development: In 2023, the FDA approved dapagliflozin for broader CKD indications, marking a milestone as clinical data showed a 39% reduction in risk of kidney failure in pivotal trials.

COVID-19 IMPACT

Chronic Kidney Disease (CKD) Drugs Market Industry Had a positive impact due to technologies & advancements during COVID-19 Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing Higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market decline reflected by the rise in CAGR is attributable to the market’s decline and demand returning to pre-pandemic levels.

Also, the Chronic Kidney Disease (CKD) Drugs Market witnessed a slew of changes brought in by the COVID-19 pandemic. For example, the pandemic was the catalyst that upped the general market awareness in terms of keeping the kidney healthy and investing in the healthcare infrastructure sector. Upsurge in the number of COVID-19-induced kidney injuries created a far bigger demand for CKD medications, specifically those prescribed for complications management. Pharmaceutical companies poured in funds for faster R&D programs, leading to the discovery of new drugs and their approval, during the viral outbreak. Further, telemedicine adoption grew, too, making it easier for more people to access CKD treatments and improving the process for continuing care among patients. In the end, as far as everyone is concerned, it mentioned how the outbreak highlighted the critical necessity for effective CKD drugs in the marketplace.

LATEST TREND

Market for Chronic Kidney Diseases Drugs is currently being characterized by such trends as precision medicine that was incorporated with SGLT2 inhibitors as well as the implementation of digital health technologies in managing patient needs. Among them, introduction of SGLT2 inhibitors is the most outstanding as it enables only the leashing of blood sugar levels in the body of the diabetic patient but also makes a significantly slower progression of CKD in the same patient. Even in non-diabetic patients, one drug, dapagliflozin, empagliflozin, has been accepted and reviewed for broader applications of CKD. The development of personalized therapies and combination technology solutions for RTCTD is definitely shaping this particular market. The progress toward targeted treatment is affecting patient outcomes and redefining the management of CKD.

• • 

    Request a Free sample to learn more about this report.

CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET SEGMENTATION

By Type

Based on Type, the global market can be categorized into ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers: BREVIBLOC, Bystolic, Others

• ACE Inhibitors

ACE inhibitors (Angiotensin-Converting Enzyme inhibitors) are medications used to treat high blood pressure and heart failure by relaxing blood vessels. They work by inhibiting the enzyme that produces angiotensin II, a chemical that narrows blood vessels. Common drugs in this category include Lisinopril, Enalapril, and Ramipril. They are widely prescribed for managing hypertension and reducing the risk of heart attacks and strokes.

• Angiotensin-II Receptor Blockers (ARBs)

ARBs block the effects of angiotensin II, preventing blood vessels from narrowing and helping lower blood pressure. They are often prescribed as an alternative to ACE inhibitors for patients who experience side effects like coughing. Common ARBs include Losartan, Valsartan, and Telmisartan. These drugs are effective for treating hypertension, chronic kidney disease, and heart failure.

• Calcium Channel Blockers

Calcium channel blockers (CCBs) prevent calcium from entering heart and blood vessel walls, resulting in relaxed and widened arteries. They are commonly used to treat high blood pressure, angina, and arrhythmias. Examples include Amlodipine, Verapamil, and Diltiazem. These drugs are particularly effective for elderly patients or those with certain forms of hypertension.

• Beta Blockers: BREVIBLOC, Bystolic

Beta blockers reduce heart rate and blood pressure by blocking the effects of adrenaline on beta receptors. BREVIBLOC (Esmolol) is used in emergency settings for rapid heart rate control, while Bystolic (Nebivolol) is prescribed for long-term management of hypertension. They are also helpful in managing heart failure, arrhythmias, and post-heart attack care. These medications are vital for reducing the heart's workload and preventing cardiovascular events.

• Others

This category includes various drugs that do not fall into the primary classes but are used for cardiovascular conditions, such as direct renin inhibitors and vasodilators. Examples include Aliskiren for hypertension and Hydralazine for heart failure. These drugs are often used in combination therapies when other treatments are insufficient. They provide additional options for personalized care in managing cardiovascular diseases.

By Application

Based on application, the global market can be categorized into Hospitals, Specialty Clinics

• Hospitals : Unmanned Ground Vehicles (UGVs) in hospitals are used for tasks such as delivering medications, transporting medical supplies, and disinfecting rooms to reduce human contact. These robots improve operational efficiency and ensure safety, especially during pandemics or outbreaks. Their adoption enhances patient care by freeing up healthcare staff for critical tasks.
• Specialty Clinics : In specialty clinics, UGVs assist with inventory management, delivering specialized medical tools, and supporting telemedicine operations. They are particularly useful in streamlining workflows in high-precision environments such as oncology and orthopedics. UGVs help clinics maintain hygiene standards and optimize resource utilization.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving Factors

Rising Prevalence of Diabetes and Hypertension

Diabetes and hypertension are leading causes of chronic kidney disease, with their global prevalence steadily increasing due to lifestyle changes and aging populations. This has significantly expanded the demand for CKD drugs aimed at managing these underlying conditions and slowing kidney damage. The link between metabolic disorders and CKD has driven pharmaceutical companies to focus on developing innovative, multi-functional treatments. This trend continues to fuel growth in the CKD drugs market.

Advancements in Drug Development

Continuous research and development efforts have led to the introduction of advanced therapies like SGLT2 inhibitors and endothelin receptor antagonists, which effectively manage CKD and its complications. These novel drugs offer dual benefits, such as improved kidney function and cardiovascular protection, enhancing their market potential. Regulatory support, faster drug approvals, and breakthroughs in precision medicine are further accelerating the growth of the CKD drugs market.

Restraining Factor

High Treatment Costs

The high cost of CKD market growth & medications and therapies limits accessibility for many patients, particularly in low- and middle-income countries. Expensive advanced drugs like SGLT2 inhibitors and biologics strain healthcare budgets and deter widespread adoption. Limited affordability and inadequate insurance coverage further impede market growth in economically disadvantaged regions.

Opportunity

Rising Focus on Preventive Care

The focus on prevention is a welcomed market expansion in highlighting the early detection and preventive care for CKD; innovations in diagnostic tools with the added integration of biomarkers have made it possible to diagnose early-stage CKD effectively. This collaboration with government initiatives and public awareness programs will drive the demand and improve outcomes for patients needing CKD drugs. Shifting to proactive healthcare, this is certainly one very attractive market landscape to look for and can result in sizable improvements in patients' treatment outcomes.

Challenge

Lack of Awareness

One of the main challenges in the CKD drug market is a lack of and less awareness about the disease and early symptoms and available treatment option. It is a real issue with many people staying undiagnosed until the situation progresses to an advanced state, which fails out the efficacy of the interventions even more. In this viewpoint, it delays good patient outcomes and also inhibits the adoption of CKD therapies in the market.

• • 

    Request a Free sampleto learn more about this report.

•  

CHRONIC KIDNEY DISEASE (CKD) DRUGS MARKET REGIONAL INSIGHTS

North America

North America dominates the Chronic Kidney Disease (CKD) Drugs Market due to its advanced healthcare infrastructure, high prevalence of CKD, and robust R&D activities. Among North American countries, the United States plays a pivotal role, driven by increasing investment in drug development and early adoption of innovative therapies. The United States Chronic Kidney Disease (CKD) Drugs Market is fueled by strong support from regulatory bodies like the FDA and growing awareness initiatives. This leadership position is further strengthened by the availability of advanced treatments and healthcare access.

Europe

It appears as though Europe can be very instrumental in the CKD Drugs Market share as it can manage research, innovation, and well-established healthcare systems. The trend comes as new advanced treatments, such as SGLT2 inhibitors, are gradually getting recognition by the region, supported by the words mouthed by regulatory agencies like the European Medicines Agency (EMA). It is also foreseen that increased public awareness and an increase in the aging population will push the demand for specialized treatments in any of the European countries.

Asia

Asia seems to be making good waves as one of the high-profile financial backers contributing to the CKD Drugs market. The improvement here is because of an increasing population and cases of diabetes and hypertension that are major risk factors for CKD. It is not only growing fast among its populations but among countries such as China and India, by being more equipped for healthcare and by increased identification of CKD Switzerland has a possibility to increase pharmaceutical markets. Health expenditures and campaigns to heighten public awareness may therefore help improve their opportunities as far as urban centers are concerned.

KEY INDUSTRY PLAYERS

Major companies representing the pharmaceutical giant in the Chronic Kidney Disease (CKD) market are launching innovative strategies to drive treatment options and make possible better clinical outcomes in invasive research. Some of the leading pharmaceutical companies-the AstraZeneca, Novo Nordisk, and Travere Therapeutics-have led the way as the pre-eminent developers of rare drugs that have the ability to slow CKD progression and manage complications such as heart disease. For example, AstraZeneca's Farxiga (dapagliflozin) and Novo Nordisk's Ozempic (semaglutide) are two brands that have truly revolutionised the treatment landscape, not only for diabetes but for CKD patients as well, since several studies already show efficacy with these drugs in protecting kidney function. Nonetheless, industry participants have also done other outstanding works by creating predictable drugs and providing a focus-based approach in treating CKD because these innovations are classed into precision medicine, biomarker-based therapies, and personalized treatment regiments that are then highly tailored to the very individual's patient profile for very good efficacy. In addition, company players collaborate with regulatory authorities, healthcare professionals, and universities to create faster approval processes for superior treatments. The growth of the market will take place as major industry players educate people about CKD disorders, the importance of early detection and treatment. This along with research and innovation into the development of CKD drugs is fuelling the growth of the global market. Furthermore, their expansion in emerging markets, especially in Asia and Latin America, is significantly step-up connected therapies' penetration and further push market growth and bring CKD drugs closer to overall greater patient coverage.

List of Market Players Profiled

• Amgen - United States
• Roche - Switzerland
• GlaxoSmithKline (GSK) - United Kingdom
• Allergan - United States
• AbbVie - United States

KEY INDUSTRY DEVELOPMENT

Novo Nordisk's Ozempic Receives EU Endorsement: In December 2024, Novo Nordisk's diabetes medication, Ozempic, received backing from the European Medicines Agency (EMA) for a label expansion. This endorsement highlights Ozempic's potential to reduce the risk of kidney disease-related conditions in adults with Type 2 diabetes. The decision was based on clinical trials demonstrating that Ozempic can slow the progression of chronic kidney disease and decrease the risk of kidney failure, heart attack, stroke, and death in such patients.

Travere Therapeutics' Filspari Gains Full FDA Approval: In September 2024, Travere Therapeutics announced that its kidney disease treatment, Filspari, received full approval from the U.S. Food and Drug Administration (FDA). Initially granted accelerated approval for treating IgA nephropathy patients at risk of rapid progression, the removal of this limitation expands Filspari's target population in the U.S. to over 70,000 patients. This approval is expected to significantly boost the drug's market potential.

REPORT COVERAGE       

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

This research report examines the segmentation of the market by using both quantitative and qualitative methods to provide a thorough analysis that also evaluates the influence of strategic and financial perspectives on the market. Additionally, the report's regional assessments consider the dominant supply and demand forces that impact market growth. The competitive landscape is detailed meticulously, including shares of significant market competitors. The report incorporates unconventional research techniques, methodologies and key strategies tailored for the anticipated frame of time. Overall, it offers valuable and comprehensive insights into the market dynamics professionally and understandably.